Results from early stage trials of the COVID-19 vaccine being developed by the University of Oxford seem promising, but will this help boost markets hoping for an eventual remedy to the recent economic downturn? Envysion Wealth Management's CIO Jacob Doo joined us on MoneyFM 89.3's Prime Time to talk about why there may be short-term bumpiness down the road, why earnings still matter despite the dour outlook, and if wealthier clients and family offices are starting to cash out on the recent equity rally.

<p>Results from early stage trials of the COVID-19 vaccine being developed by the University of Oxford seem promising, but will this help boost markets hoping for an eventual remedy to the recent economic downturn? Envysion Wealth Management's CIO Jacob Doo joined us on MoneyFM 89.3's Prime Time to talk about why there may be short-term bumpiness down the road, why earnings still matter despite the dour outlook, and if wealthier clients and family offices are starting to cash out on the recent equity rally.</p>

Advertisement